Ra Pharma commences mid-stage study of zilucoplan in rare type of myopathy

Dosing is underway in a 24-subject Phase 2 clinical trial evaluating Ra Pharmaceuticals’ (NASDAQ:RARX) zilucoplan for the treatment of immune-mediated necrotizing myopathy, a rare type of idiopathic (cause unknown) inflammatory myopathy (muscle fiber dysfunction) characterized by muscle weakness, necrosis (uncontrolled cell death) and elevated creatinine kinase (CK) levels.

The primary endpoint is the change from baseline in CK levels at week 8 versus placebo. The estimated primary completion date is November 2020.

https://seekingalpha.com/news/3523600-ra-pharma-commences-mid-stage-study-of-zilucoplan-in-rare-type-of-myopathy